- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04115514
Trattamento di ARDS con T3 instillato (ARDS+T3)
Studio di fase II randomizzato, intervento contro non intervento, multicentrico sugli effetti dell'ormone tiroideo (T3) sull'acqua polmonare extravascolare (EVLW) in soggetti con sindrome da distress respiratorio acuto (ARDS)
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
Panoramica dello studio
Stato
Descrizione dettagliata
T3 Therapy in ARDS- Phase 2 Randomized, Unblinded, Intervention versus Non- Intervention Trial. Enrollment 68 participants (50 treatment + 18 control). Purpose- To determine the safety and tolerability of T3 delivery into the lungs of ARDS patients, and to measure the effect of T3 on Oxygenation in ARDS patients. Study Drug- Liothyronine Sodium (T3), 50 mcg will be instilled twice daily via a catheter through the ETT into the airway in a total volume of 10 mL (T3+0.9% sodium chloride), over 5 days (10 total doses), or until extubation, whichever comes first.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Minnesota
-
Edina, Minnesota, Stati Uniti, 55435
- M Health Fairview Southdale Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55455
- East Bank Hospital - M Health Fairview University of Minnesota Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Study population is critically ill patients requiring mechanical ventilatory support for ARDS in an intensive care unit.
-
Adults (≥18 years of age).
-
Male or female (non-pregnant).
-
Clinical diagnosis of ARDS (all are required):
- Onset: <= 7 days.
- Chest x-ray: Bilateral Patchy Opacities, Infiltrates.
- Mechanical Vent Support: PEEP or CPAP Support >= 5 cm H2O.
- Pulmonary Edema: Not fully explained by cardiogenic etiology.
- Hypoxia: PaO2/FIO2 Ratio <300, or O2Sat/FIO2 Ratio <315.
-
On mechanical ventilatory support.
-
Capable of giving informed consent directly or from the subject's legally authorized representative (LAR) as determined by the site Principal Investigator and/or Sub- Investigators.
Exclusion Criteria:
Patients with any of the following conditions will be excluded from this trial:
-
Inadequate medical history for determining inclusion/exclusion criteria, as determined by the Principal Investigator and/or Sub- Investigators.
-
Unlikely to complete the protocol with clinic follow-up after discharge, as determined by the Principal Investigator and/or Sub- Investigators or hospice status.
-
Prior history of thyroid cancer or hyperthyroidism, per thorough patient/family interviews, review of past medical history, medication list, laboratory test.
-
Prior history of cardiovascular disease defined as:
- Hypertensive crisis in the past 3 months (systolic >200, or diastolic >120 mmHg),
- Sustained ventricular arrhythmia in the past 3 months (duration >30 seconds)
- Coronary artery disease (documented >=70% occlusion untreated in any coronary vessel), as per the 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization.
- Cardiac-related angina pectoris (>=2 episodes in the past 3 months)
- Myocardial infarction with ischemia on ECG (i.e.,new ST- elevation/depression of >1mm in contiguous leads).
- Peripheral vascular disease (documented >=70% occlusion untreated in any peripheral vessel), as per the 2018 ACC/AHA/SCAI/SIR/SVM Guidelines for Appropriate Use Criteria for Peripheral Artery Intervention.
- Decompensated or symptomatic heart failure (i.e., hospitalized for CHF exacerbation, or a change in CHF medications within two weeks prior)
-
Currently pregnant or breastfeeding.
-
Known allergy to study drug.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Treatment Arm
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation. |
Study Drug Administration:
|
|
Altro: Control arm
Standard of Care |
Standard of Care (SOC) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: baseline
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
baseline
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: 6 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
6 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: 12 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
12 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: 24 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
24 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: 48 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
48 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: 72 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
72 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: 96 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
96 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Lasso di tempo: 120 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
120 hours post-dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose/i del/i pressore/i SOC
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
Dose(i) di diuretico(i) SOC
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
Giorni senza ventilatore
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
Giorni liberi dalla terapia intensiva
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
Giornate senza ossigeno
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
Mortalità per tutte le cause
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
Requisito per il posizionamento della tracheotomia
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
TSH, T3 totale, T3 libero, T4 libero
Lasso di tempo: basale e 156 ore dopo la dose
|
basale e 156 ore dopo la dose
|
|
|
T3 libero, T4 libero
Lasso di tempo: basale e 5 giorni
|
basale e 5 giorni
|
|
|
Pulmonary events
Lasso di tempo: baseline and 120 hours post-dose
|
Progressive hemoptysis: bright, red blood in streaks, mixed or clots within sputum on suctioning of greater than 30 mL accumulation anytime following the initial and subsequent intratracheal dosing administrations. |
baseline and 120 hours post-dose
|
|
Cardiovascular event 1
Lasso di tempo: baseline to 120hours post-dose
|
New sustained ventricular arrhythmia (>30 secs) |
baseline to 120hours post-dose
|
|
Cardiovascular event 2
Lasso di tempo: baseline to 120hours post-dose
|
New sustained accelerated junctional arrhythmia (rate >80 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 3
Lasso di tempo: baseline to 120hours post-dose
|
New sustained atrial fibrillation with rapid ventricular response (ventricular rate >160 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 4
Lasso di tempo: baseline to 120hours post-dose
|
Cardiac arrest (pulseless electrical activity, or asystole). |
baseline to 120hours post-dose
|
|
Cardiovascular event 5
Lasso di tempo: baseline to 120hours post-dose
|
Hypertensive crisis (systolic pressure of 180 mmHg (or higher), or diastolic pressure of 120 mmHg (or higher) or change in MAP > 20 mmHg with three consecutive measurements over 30 minutes). |
baseline to 120hours post-dose
|
|
SOC pulmonary vasodilator
Lasso di tempo: baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Supplemental oxygen on discharge
Lasso di tempo: baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Discharge disposition
Lasso di tempo: baseline and 5 days
|
home, inpatient rehabilitation, long-term acute care hospital (LTACH) |
baseline and 5 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: David H Ingbar, MD, University of Minnesota
- Direttore dello studio: Timothy P Rich, MD, University of Minnesota
- Investigatore principale: Ronald A Reikoff, MD, University of Minnesota
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Infezioni delle vie respiratorie
- Infezioni
- Malattie delle vie respiratorie
- Malattie polmonari
- Disturbi respiratori
- Malattie della tiroide
- Sindrome da stress respiratorio
- Edema polmonare
- Polmonite
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Aminoacidi, peptidi e proteine
- Aminoacidi
- Aminoacidi, aromatici
- Aminoacidi, ciclici
- Ormoni tiroidei
- Tironine
- Tiroxina
- Triiodotironina
Altri numeri di identificazione dello studio
- PACS-2020-23242
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .